Microsatellite Instability: all 52 studies

Page 1 of 1. Open to participants first (10), then studies with results posted, then the rest; newest registration first within each.

• Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual DiseaseRecruitingNCT07750158Phase 3
• A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.RecruitingNCT06898450Phase 1/2
• PRODIGE 90 - (FFCD 2204) Neoadjuvant Dostarlimab with Short Course Radiotherapy in a Watch-and-wait Strategy for Microsatellite Unstable or Mismatch Repair-deficient Locally Advanced Rectal Cancer PatientsRecruitingNCT06762405Phase 3
• Neoadjuvant Pembrolizumab With a Watch-and-wait Strategy for dMMR/MSI-H Localized Colon Cancer: PREMICES Study.Not yet recruitingNCT06646445Phase 2
• Prospective National Cohort Evaluating Predictive Biomarkers of Resistance to Immunotherapy in Patients With MSI/dMMR Metastatic Colorectal Cancer (CORESIM)RecruitingNCT06353854
• MMR/MSI Phenotypes in Prediction of Tumor Vaccine Benefit for GliomasRecruitingNCT06043232
• A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid TumorsRecruitingNCT06004245Phase 1
• Non-Invasive Diagnosis of Endometrial CancerRecruitingNCT05737797Not applicable
• A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid TumorsRecruitingNCT05592626Phase 1/2
• Anti-PD-1 and CapOx for the First-line Treatment of dMMR Esophagogastric Cancer (AuspiCiOus)RecruitingNCT05177133Phase 2
• Pembrolizumab in MMR-Proficient Metastatic Colorectal Cancer Pharmacologically Primed to Trigger Hypermutation StatusCompletedNCT03519412Phase 2Results posted
• M7824 in Patients With Metastatic Colorectal Cancer or With Advanced Solid Tumors With Microsatellite InstabilityCompletedNCT03436563Phase 1/2Results posted
• Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected CancersCompletedNCT02178722Phase 1/2Results posted
• Liquid Biopsy Biomarkers for Endoscopic Surveillance in Lynch SyndromeCompletedNCT07838246
• Development and Validation of the Surgical Assessment and Healthcare (SAH) Index for Gastric Cancer Treatment EvaluationCompletedNCT07180966
• First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined CancersTerminatedNCT06625515Phase 1
• Neoadjuvant Prolgolimab Monotherapy in Locally Advanced MMR-deficient Colorectal CancerCompletedNCT06428487Phase 2
• Dynamics of MSI and Genomic Profile of Colorectal Cancer In the Course of Immune Checkpoint Inhibitor TherapyCompletedNCT06414304
• Molecular Characteristics of Early-onset Compared With Late-onset Colorectal CancerCompletedNCT06238193
• National Cohort of Colorectal Cancers With Microsatellite InstabilityCompletedNCT05511688
• Frequency of Endometrial Cancer Precursors Associated with Lynch SyndromeCompletedNCT05257057
• Microsatellite Instability in Colorectal CancersCompletedNCT05162248
• TremelImumab aNd Durvalumab For the Non-operatIve Management (NOM) of MSI-high Resectable GC/GEJC.Active, not recruitingNCT04817826Phase 2
• Genetic Mutation in Epithelial Ovarian CancerStatus unknownNCT04191252
• Genetic Mutation in Recurrent Cervical CancerStatus unknownNCT04191226
• Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular ImmunotherapyTerminatedNCT04106167
• Pre-operative Nivolumab and Ipilimumab, Followed by Post-operative Nivolumab, for MSI/dMMR Oeso-gastric Adenocarcinoma.Active, not recruitingNCT04006262Phase 2
• Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid CancersActive, not recruitingNCT03935893Phase 2
• FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid TumorsCompletedNCT03841110Phase 1
• Avelumab Plus 5-FU Based Chemotherapy as Adjuvant Treatment for Stage 3 MSI-High or POLE Mutant Colon CancerTerminatedNCT03827044Phase 3
• Clinicopathological Importance of Colorectal Medullary Carcinoma: Retrospective Cohort StudyCompletedNCT03774862
• MSI in Circulatory DNA of Endometrial CancerStatus unknownNCT03744962
• Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 InhibitorActive, not recruitingNCT03607890Phase 2
• Detection of MSI in Circulating Tumor DNA of Colorectal Carcinoma PatientsTerminatedNCT03594448
• Detect Microsatellite Instability Status in Blood Sample of Advanced Colorectal Cancer Patients by Next-Generation SequencingStatus unknownNCT03561350
• A Safety and Tolerability Study of INCAGN02385 in Select Advanced MalignanciesCompletedNCT03538028Phase 1
• Cycling in Preventing Colorectal Cancer in Participants With Lynch SyndromeCompletedNCT03495674Not applicable
• The Relationship Between Microsatellite Instability and Efficacy of Fluorouracil Based Adjuvant Chemotherapy in Gastric Cancer After OperationCompletedNCT03485196
• Aberrant Splicings Due to Microsatellite Instability in Colorectal Cancer : Physiopathological and Clinical ImpactStatus unknownNCT03447431
• iRECIST Evaluation's Relevance for DCR in MMR/MSI Metastatic Colorectal Cancer Patients on Nivolumab and IpilimumabActive, not recruitingNCT03350126Phase 2
• QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint InhibitorsActive, not recruitingNCT03228667Phase 2
• APL-501 Study for Select Advanced or Relapsed/Recurrent Solid TumorsCompletedNCT03053466Phase 1
• Diagnosis of Lynch Syndrome Based on Next-generation Sequencing in Colorectal CancerCompletedNCT03047226
• Secured Access to Nivolumab for Adult Patients With Selected Rare Cancer TypesCompletedNCT03012581Phase 2
• Durvalumab in Treating Patients With Metastatic Hormone-Resistant Prostate CancerWithdrawnNCT02966587Phase 2
• Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)Active, not recruitingNCT02628067Phase 2
• Molecular Biology of Anal Cancer in HIV-Positive PatientsCompletedNCT00952874
• Postoperative Radiotherapy According to Molecular Analysis of Surgical Margins of Oral and Oropharyngeal SCCStatus unknownNCT00232960Not applicable
• Clinical and Molecular Characterization of Familial Microsatellite Stable Colorectal CancerStatus unknownNCT00220246
• Association of MSI, TS, DPD, MVD and EGFR With Chemosensitivity in Stage IV in Colorectal CancerStatus unknownNCT00173472
• Association of Colorectal Cancer With Nutrition, Diet, Obesity, Diabetes Mellitus, and Genetic Alterations in TaiwanStatus unknownNCT00172757
• Implementation of a New Strategy to Identify HNPCC PatientsStatus unknownNCT00141466Not applicable

← Microsatellite Instability overview